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Introduction
Metal-based compounds have been largely used and studied
as chemotherapeutic drugs since the discovery of the cytotoxic
properties of cisplatin (cis-[Pt(NH3)2Cl2]) in the late 1960s;
[1–3]
after its approval by the US Food and Drug Administration in
1978, cisplatin has become a milestone in antineoplastic treat-
ment.[3, 4] The therapeutic relevance of platinum-based com-
pounds has led researchers to elucidate their mechanisms of
action, with the aim to improve their efficacy on neoplasms
and to hamper adverse reactions in healthy tissues.
It is known that the metal center in metal-based drugs is the
pivotal moiety that acts as the anticancer “weapon”, whereas
the organic part of the molecule (ligand) plays other key roles,
such as stabilizing the metal oxidation state, reducing systemic
toxicity, and tuning water solubility. Under physiological-like
conditions, metal centers, being positively charged, are favored
to bind to negatively charged biomolecules, such as enzymes
and nucleotides, or undergo redox processes.[5–8] On the other
hand, the mechanism of biological action of metal compounds
is, in several cases, not fully elucidated. As an example, in anti-
cancer metallodrugs, DNA is not always the primary target as
it appears for cisplatin.[6–9] In addition, the type of ligands (O-,
N-, S-donors, monodentate or chelating ones, etc.), the nature,
and the oxidation state of the metal center determine the hall-
marks of the final compound such as its coordination geome-
try and stereochemistry and, ultimately, its biological behav-
ior.[10–14] These observations, together with the poor toxicologi-
cal profile of cisplatin, whose clinical use causes adverse effects
and the occurrence of resistance,[15, 16] have prompted the re-
search into alternative platinum-based compounds, in order to
find drugs with a better chemotherapeutic index in terms of
toxicity–activity ratio.[15,17,18]
In the last years, we have broken into this research scene
with our nonplatinum-based coordination compounds. These
molecules are metal–dithiocarbamato (dtc) complexes poten-
tially able to combine the cytotoxic activity of the related
metal center (e.g. AuI,III, RuII,III, ZnII, CuII) with lack of toxicity
owing to the inherent chemoprotective action of the dtc
ligand.[19,20] Overall, our findings provide evidence for the im-
portance of stabilizing the heavy metal center in order to pre-
vent its nonspecific reactivity that would give rise to systemic
toxicity.[21] Up to now, the most promising results have been
obtained with gold(III) derivatives of the type [AuIIIX2(dtc)] (X=
Cl, Br ; dtc=various dithiocarbamato ligands). These com-
pounds closely reproduce the structural features of cisplatin,
and most of them are endowed with good anticancer activity,
together with a very low or negligible systemic toxicity.[22–26]
In parallel to the synthesis of gold chemotherapeutics, we
have also been synthetizing and studying coordination com-
pounds of ruthenium and copper with pyrrolidinedithiocarba-
Transition metals offer many possibilities in developing potent
chemotherapeutic agents. They are endowed with a variety of
oxidation states, allowing for the selection of their coordina-
tion numbers and geometries via the choice of proper ligands,
leading to the tuning of their final biological properties. We
report here on the synthesis, physico-chemical characteriza-
tion, and solution behavior of two gold(III) pyrrolidinedithiocar-
bamates (PDT), namely [AuIIIBr2(PDT)] and [Au
IIICl2(PDT)] . We
found that the bromide derivative was more effective than the
chloride one in inducing cell death for several cancer cell lines.
[AuIIIBr2(PDT)] elicited oxidative stress with effects on the per-
meability transition pore, a mitochondrial channel whose
opening leads to cell death. More efficient antineoplastic strat-
egies are required for the widespread burden that is cancer. In
line with this, our results indicate that [AuIIIBr2(PDT)] is a promis-
ing antineoplastic agent that targets cellular components with
crucial functions for the survival of tumor cells.
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mate (PDT) as a ligand. In this context, we found that the pres-
ence of PDT strongly affects the final biological activity. In fact,
we recorded an encouraging cytotoxic activity in the nano and
micromolar range against human non-small-cell lung cancer,
two estrogen-receptor-a-positive breast cancer cell lines, the
triple negative MDA-MB-231 breast cancer cell line, androgen-
receptor-independent prostate tumor, ovarian and cervical
squamous carcinoma cell lines, and the corresponding cispla-
tin-resistant subclones.[27,28] Therefore, in the present work we
have combined the chelating ligand PDT with gold metal in
a 1:1 metal-to-ligand stoichiometry with the remaining coordi-
nation sites occupied by two cis-halogen ions which may un-
dergo hydrolysis in the physiological milieu.
In particular, we report on the synthesis of two new gold(III)
pyrrolidinedithiocarbamates with the general formula
[AuIIIX2(PDT)] as shown in Figure 1, wherein X is either Br (com-
plex 1) or Cl (complex 2). Their physico-chemical characteriza-
tion was followed by the evaluation of their in vitro cytotoxici-
ty on HeLa (cervical cancer), HCT116 (colon neoplasia), SAOS
(osteosarcoma), and MEF-NF1¢/¢ (immortalized primary embry-
onic fibroblast) cancer cell lines. The solution behavior of both
complexes was also studied under physiological-like conditions
by UV/Vis spectrophotometry. Then, the cell-death-inducing
mechanisms were explored by investigating whether the com-
pounds affect redox equilibrium or influence the mitochondrial
permeability transition pore (PTP) activity.
Results and Discussion
Synthesis and characterization of the gold(III) complexes
Two gold(III)-pyrrolidinedithiocarbamato derivatives were pre-
pared in very good yields via direct reaction of the salt ligand
ammonium PDT with the metal precursor potassium tetrabro-
moaurate(III) or potassium tetrachloroaurate(III) under equimo-
lar conditions at room temperature. The purity of all final com-
pounds was higher than 95% (by thermogravimetric and ele-
mental analysis). Both the starting ammonium PDT and the
corresponding gold(III)-dithiocarbamato derivatives 1 and 2
(Figure 1) have been characterized by means of several tech-
niques in order to confirm the expected stoichiometry as well
as to investigate their structural features.
Elemental and thermogravimetric analyses highlighted
a very good correlation between calculated and found values.
In particular, thermal degradation primarily takes place via two
steps, leading to the formation of metallic gold, in agreement
with literature data[29,30] (Table 1). The presence of an endother-
mic differential scanning calorimetry (DSC) peak at about
1064 8C (gold Tmelt) along with no weight loss further confirms
the decomposition to elemental gold. The first step is likely
due to the formation of gold(I) thiocianate upon reductive
elimination as reported in literature for similar gold(III) dithio-
carbamato compounds.[31,32]
The elucidation of the coordination mode and the strength
of the bonds between the metal and the ligand donor atoms
is of paramount importance in the characterization of metal
derivatives designed for medicinal applications. In this regard,
medium and far FT-IR spectroscopy are among the best diag-
nostic tools. Table 2 highlights that the band associated with
the N¢CSS stretching shifts toward higher energies when pass-
ing from the free ligand to the corresponding gold derivatives
due to an increased carbon–nitrogen double bond character
following the coordination.[33–35] The detection of a single band
at about 1000 cm¢1, attributable to the na (S¢C¢S) for both
gold(III) complexes, points out that the ¢NCSS moiety chelates
the metal center in a symmetrical bidentate mode in agree-
ment with our data on other complexes.[21,24,36] A band, detect-
able in the range 420–630 cm¢1 and commonly ascribed to the
ns (S¢C¢S) vibration, is observed for both the complexes and
the free dithiocarbamato ligand (Table 2).[29,37–40] It is interesting
to underline that this absorption is associated also with some
MhssiC ring deformations, as previously shown by detailed FT-IR
isotopic studies on various dithiocarbamato complexes.[41] The
presence of two new bands in the range 370–420 cm¢1, absent
in the IR spectrum of the free ligand and ascribable to
gold(III)–sulfur vibrations (ns and na), further accounts for a che-
lated coordination geometry.[38] Notably, on the basis of the en-
ergies recorded for the na/s (S¢Au¢S), compound 2 is character-
ized by a slightly stronger metal–ligand bond, which indirectly
determines a higher stretching frequency for the N¢CSS bond
(Table 2).[42] Two halides complete the coordination sphere in
Figure 1. Chemical structures of the synthesized gold(III) complexes.
Table 1. TG and DSC data for the gold(III)-dithiocarbamato compounds
1 and 2.
Cmpd Weight loss to Au(0) [%] Peak temperature (process)[a] [8C]
Calculated Found
1 ¢60.91 ¢60.95 261 (endo); 497 (exo); 1064 (endo)
2 ¢52.21 ¢51.91 242 (endo); 495 (exo); 1064 (endo)
[a] Endo=endothermic, exo=exothermic.
Table 2. Selected FT-IR frequencies of the ligand PDT and the corre-
sponding gold(III)-dithiocarbamato compounds 1 and 2.
Cmpd Vibrational mode [cm¢1]
na/s
NH4
+
n
N¢CSS
na/s
SCS
na/s
SAuS
na/s
XAuX
NH4(PDT) 3102
[a] 1412 988/565 — —
1 — 1583 943/537 411/371 240/218[b]
2 — 1586 942/538 413/375 362/315[c]
[a] NH4
+ ; [b] X=Br; [c] X=Cl.
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a cis-geometry as shown by the appearance of two new bands
(na/s (X¢Au¢X)) at 240/218 and 362/315 cm¢1 for the complex 1
and 2, respectively.[43,44] The other main frequencies, ascribable
to the organic alkylic backbone, seem to be negligibly affected
by metal coordination, except for the disappearance of the
broad band at 3102 cm¢1 (na/s (NH4
+)) (Table 2).
Concerning the NMR characterization, one and two-dimen-
sional spectra (1H,13C HMBC, Table 3) showed an upfield shift
(about 20 ppm with respect to the free ligand) for the signal
of the dithiocarbamato carbon atom for both complexes (at
about 190 ppm), along with the disappearance of the NH4
+
proton peak (at 7.33 ppm), confirming the formation of the
gold(III) derivatives. In comparison with the spectrum recorded
for ammonium PDT, all 13C resonances are shifted at higher
fields. Conversely, upon metal coordination the 1H multiplets
of all the methylene groups are shifted at lower fields, thus
pointing out opposite shield effects on the two investigated
NMR-active nuclei. By means of NMR kinetics, we checked the
stability over time of both complexes in D6-dimethylsulfoxide
(DMSO) as predissolution of our hydrophobic compounds in
this organic solvent is necessary to carry out the biological
tests in cell culture medium.
UV/Vis spectrophotometric studies
When studying metallodrugs, it is necessary to test their stabil-
ity under physiological conditions.[5] Therefore, detailed spec-
trophotometric studies were carried out for both complexes
dissolved in DMSO (reference solvent) and saline solution. In
order to better investigate the possible reactivity in both
media, several electronic spectra were recorded up to 24
hours. It is worth pointing out that our compounds show
a good antiproliferative activity already after a few hours of
treatment.[22] Accordingly, in this work we highlight only the
chemical and biological behavior after a three-hour treatment.
The kinetic behavior of the coordination compounds 1 and 2
was first monitored in DMSO (Figure 2) at 37 8C and a concen-
tration of 100 mm (main features collected in Table 4).
Band 1 and band 2 have been ascribed in literature to intrali-
gand p* !p transitions mainly located in the ¢NCS and ¢CSS
moieties, respectively.[29,38] Moreover, an intraligand p* !n tran-
sition, where n is the in-plane nonbonding sulfur orbital,
should be recorded at around 340 nm[45] but is not observable
owing to the overlap with the more intense adjacent bands. A
weak band at about 380 nm is visible only for the coordination
compound 1 (labeled as band 3 in Figure 2) and is attributable
to an intramolecular L !M charge transfer involving the M nd
orbitals and the dithiocarbamato p* system.[46,47] However,
Table 3. 13C NMR spectral data of the ligand PDT and compounds 1 & 2.
Cmpd d [ppm]
R¢N ¢CSS
NH4(PDT) 26.06 (CH2CH2N)
53.00 (CH2CH2N)
208.81
1 23.35 (CH2CH2N)
50.87 (CH2CH2N)
188.32
2 23.41 (CH2CH2N)
51.10 (CH2CH2N)
188.58
Figure 2. UV/Vis spectra recorded for compounds 1 (a) and 2 (b) in DMSO at 37 8C.
Table 4. Main absorption bands (evaluated at time zero) in the UV/Vis
electronic spectra acquired in DMSO and saline solution at 37 8C.
Compound Solvent lmax [nm]
Band 1 Band 2
1 DMSO 277.3 319.0
Saline solution 269.3 311.6
2 DMSO 268.6 318.3
Saline solution 269.2 311.1
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owing to the quite high oxidizing power of AuIII, this transition
has been ascribed also to an electron transfer of the type u !g
from a 4p orbital of the bromide ligands to the lowest unfilled
5d orbital of the metal center.[48] Its low intensity can be ex-
plained by a poor overlap between the 5d metal orbital and
the involved 4p orbital (p symmetry).[48]
For both complexes, no major alteration of the bands relat-
ed to the metal–ligand chromophore was observed over time.
This behavior is likely due to the large stabilization effects
brought about by the dithiocarbamato ligand. Such stability
was further confirmed in the same solvent by 1H NMR over
three hours. On the basis of these results, DMSO was used to
dissolve 1 and 2 prior to performing all the biological tests
(<0.5% v/v) and was taken as reference medium in the discus-
sion of the spectral features detected in saline solution. In this
aqueous environment, the evolution with time was likewise
followed by UV/Vis spectrophotometry for three hours at 37 8C
(Figure 3), with both compounds being previously dissolved in
DMSO (final concentration 100 mm, at 0.8% and 1.3% v/v con-
tent of DMSO for compound 1 and 2, respectively).
Table 4 reports only the absorption data recorded at the
time zero. Similar to other our complexes,[14,49] contrary to
DMSO medium, some decreases of the band intensities were
quickly observed for both complexes upon dissolution in
saline, reaching a steady condition after three hours. Overall,
the maximum position of the bands is essentially unchanged
over time. This points out that the gold center keeps the +3
oxidation state thanks to the stabilizing effects played by the
chelating dithiocarbamato ligand.[50] The drop in spectral inten-
sity can be ascribed to the progressive hydrolysis of gold(III)-
bromide (compound 1) and gold(III)-chloride (compound 2)
bonds, leading to the water-soluble aquo complexes and, ulti-
mately, to the precipitation of the hydroxo derivatives (verified
by elemental and far FT-IR analyses). In addition, compound 1
undergoes more rapid hydrolysis compared to the complex 2
with an absorbance decrease over one hour of about 11% and
1%, respectively, (Figure 3). This behavior highlights a higher
intrinsic reactivity of the bromide derivative with respect to
the chloride one under physiological-like conditions. In fact,
bromide ranks lower than chloride within the experimental
spectrochemical series of ligands,[51] thus pointing out a greater
capacity for the latter to cause d-orbital splitting. The larger
the crystal field stabilization energy, the stronger the metal–
ligand bond, in agreement with our previously described FT-IR
data on the Au¢X bond strength.
Biological assays
Compounds 1 and 2 induce dose-dependent tumor cell death
Treatment with both compounds 1 and 2 resulted in a rapid
(three-hour) dose-dependent decrease of cell viability in the
following human cancer cell lines: the highly aggressive SAOS-
2 osteosarcoma cells, the HeLa cervical adenocarcinoma cells,
the HCT116 colorectal carcinoma cells, and the mouse embry-
onic fibroblasts, obtained from mice where the bona fide
tumor suppressor gene NF1 was genetically ablated (MEF-
NF1¢/¢) (Table 5).
Our data also show that compound 1 is the most promising
anticancer molecule, as it induced a markedly higher cytotoxic-
ity than compound 2 in all tested cell types (Figure 4, a–d),
suggesting that the presence of bromides instead of chlorides
in the gold coordination sphere profoundly affects the biologi-
cal efficacy of the potential drug. Cisplatin was tested as a refer-
Figure 3. UV/Vis spectra recorded for compound 1 in saline solution at 37 8C over 3 h (left) and the first 60 min (right).
Table 5. Growth inhibition of various cell lines after 3 h treatment with
the gold(III) compounds 1 and 2.
IC50
[a] [mM]
Cmpd SAOS-2 HeLa HCT116 MEF NF1¢/¢
1 12.21.6 17.71.6 15.82.1 3.60.9
2 26.43.1 30.84.2 43.65.4 7.81.1
Cisplatin NE[b] NE[b] NE[b] NE[b]
[a] Data represent the mean  S.D. for n=7. Cells tested were the follow-
ing: human tumor cell lines SAOS-2 (human osteosarcoma), HeLa (cervical
cancer), and HCT116 (colon neoplasia) and the immortalized primary
mouse embryonic fibroblast (MEF) model MEF-NF1¢/¢ (isolated from
knockout strains for the oncosuppressor gene neurofibromine) ; [b] NE
stands for not evaluable at 3 h treatment.
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ence compound under the same experimental conditions re-
cording no significant cytotoxicity after three hours of treat-
ment.
Compound 1 increases intracellular reactive oxygen species
(ROS) and sensitizes the permeability transition pore (PTP) to
opening
In the light of the antiproliferation screening, we then con-
ducted the subsequent biological studies on the more active
compound 1.
Recently, we have shown[52] that the gold(III)-dithiocarbama-
to complex AuL12 causes a rise of mitochondrial superoxide
levels that kills tumor cells by inducing ROS-dependent open-
ing of the PTP. The PTP is a large channel located in the inner
mitochondrial membrane, whose opening causes mitochondri-
al depolarization and swelling, leading to rupture of the outer
mitochondrial membrane, release of Ca2+ and of pro-apoptotic
proteins, and then cell death.[53,54] Therefore, we evaluated
whether the cytotoxicity elicited by compound 1 is mediated
by a similar oxidative stress, which would prompt cell death by
selectively triggering PTP opening in neoplastic cells. We per-
formed these experiments on MEF-NF1¢/¢, obtained from
knockout mice for the onco-suppressor gene NF1. Such a gene
encodes neurofibromin (Nf1), which negatively regulates
Ras,[55] a master protooncogene whose hyperactivation is the
most common oncogenic event, which prompts cell prolifera-
tion, apoptosis resistance, and metabolic rearrangements.[56] In
addition to Ras hyperactivation, the ablation of the NF1 gene
also results in the genetic disease neurofibromatosis, character-
ized by the occurrence of diverse tumor types.[57] Based on
these considerations, MEF-NF1¢/¢ cells constitute a good
model to check the antiblastic activity of our compounds.
The gold(III) compound 1 induced a rise in ROS levels (Fig-
ure 5a). Kinetic experiments showed that the ROS increase was
extremely rapid, reaching a maximum after 60 minutes (Fig-
ure 5a). To ascertain whether compound 1 is capable of elicit-
ing PTP opening, we performed a Ca2+ retention capacity
(CRC) analysis, which evaluates PTP modulation in a semiquan-
titative way through the assessment of the amount of Ca2+
taken up by mitochondria before pore opening.[58] As shown in
Figure 5b, compound 1 triggered a dose-dependent CRC de-
crease on isolated liver mitochondria, which constitutes the
standard model when setting CRC experiments, because hepa-
tocytes are endowed with a high number of mitochondria. In-
hibition of Ca2+ release from mitochondria by a control treat-
ment of cyclosporine A (CSA), a well-known PTP inhibitor, con-
firmed that CRC experiments were assessing PTP modulation,
and that the observed calcium release is due to PTP opening.
These data suggest that compound 1 seems to promote cell
death by inducing PTP opening, so we also carried out CRC ex-
periments on the MEF-NF1¢/¢ cells.[58] We found that a three-
hour treatment with the gold(III) complex 1 caused a dose-de-
pendent CRC shortening, that is PTP opening, on this cellular
model as well (Figure 5c). Furthermore, we performed parallel
experiments in the presence of the ROS-scavenging compound
Trolox, finding no changes in the effect of compound 1 on PTP
opening. These experiments suggest that the cell death com-
mitment induced by compound 1 is not only associated with
its verified ability to induce ROS, but it is likely due to other
ROS-independent pathways, that ultimately lead to PTP open-
ing.
Conclusions
In the last four decades, the unquestionable therapeutic suc-
cess of the anticancer drug cisplatin has prompted the design,
Figure 4. Compounds 1 (black bars) and 2 (grey bars) are cytotoxic to some cancer cell lines. Cell viability was measured on SAOS-2 (a), HeLa (b), and HCT116
(c) human cancer cell lines and on MEF-NF1¢/¢cells (d). Shown are dose-response experiments after a 3 h treatment with compounds 1 and 2. BAS stands for
the control. Values represent the mean  S.D. of at least n=7.
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synthesis, and biological development of several metal-based
potential chemotherapeutics. On the whole, our gold(III) com-
plexes of the type [AuX2(dtc)] (X=Cl, Br ; dtc=various dithio-
carbamates) stand out among others for their capability to
strongly inhibit tumor growth both in vitro and in vivo by
mechanisms of action differing from those recognized for the
clinically-established platinum drugs.[59]
In this work, our novel compounds 1 and 2 showed
a marked cytotoxicity towards different tumor cell types in
a short treatment time (Table 5).
In order to exploit the chemotherapeutic potential of this
class of gold(III) derivatives, it is mandatory to dissect their
mode of action on target cells. One possibility is that tumor
cell death is caused by oxidative stress. It must be underlined
that malignant cells are extremely sensitive to oxidative stress
as they are characterized by complex metabolic rearrange-
ments, with an enhancement of glucose utilization and a con-
comitant decrease of mitochondrial respiration (the Warburg
effect[60–62]). As respiratory chain complexes are the major pro-
ducers of ROS inside cells,[63] downmodulation of their activity
enhances ROS generation, forcing cancer cells to set a novel
homeostatic redox equilibrium by simultaneously inducing an-
tioxidant defenses.[64] Thus, neoplasms might be sensitized to
oxidative stress with respect to nontransformed tissues, as any
increase in ROS levels could unbalance their redox equilibrium
by overpowering their residual anti-oxidant capabilities.
In this research, we observed that the great activity of com-
pound 1 on NF1¢/¢ MEFs is paralleled by an increase in ROS
levels. This oxidative assault is able to induce the PTP, a mito-
chondrial channel whose opening commits cells to death.[54]
However, the presence of the scavenger Trolox does not affect
the ability of compound 1 to trigger the pore transition in
MEF-NF1¢/¢ cells, thus suggesting the oxidative stress can only
partially account for the efficacy of our potential drug. The
chemical behavior of both complexes was also studied under
physiological-like conditions by UV/Vis spectrophotometry in
Figure 5. Compound 1 is able to induce reactive oxygen species (ROS) and sensitize the permeability transition pore (PTP). a) Dose-response and ROS kinetics
measured on mitochondria of MEF-NF1¢/¢ treated up to 120 min with 20 mm and 40 mm of 1; values represent the mean  S.D. of at least n=5. b) Left :
changes on pore permeability transition induced by compound 1 on purified mitochondria from mouse liver and measured by calcium retention capacity
(CRC). Right: same experiments carried out in the presence of the inhibitor cyclosporine A (CSA), added 1 h before treatment. Values represent the mean 
S.D. of at least n=4. c) Left : example of a single experiment of PTP sensibility measured by a CRC assay on whole MEF-NF1¢/¢cells treated with different
doses of 1. Mitochondrial calcium uptake is plotted in terms of Calcium Green-5N fluorescence. Right: average histogram of the total Ca2+ uptake before PTP
opening (error bars represent the S.D. for n=3).
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order to gain insights into the stability of the gold(III) coordina-
tion sphere and to connect it with the degree of cytotoxicity
of the compounds. In this regard, the organic/inorganic nature
of the ligands can play a major role in modulating anticancer
properties of the metal ion. On the whole, the analysis of the
collected chemical data and their comparison with the biologi-
cal results brings out a structure–activity relationship. In partic-
ular, we found that lability of the halogen–gold bond perfectly
matches the biological effects of the complexes. In fact, it
turned out that the faster the hydrolysis process of the Au¢Br/
Cl bond, the greater the chemotherapeutic effect observed,
thus accounting for the stronger cytotoxicity of complex 1 in
comparison with complex 2. Such a phenomenon is in agree-
ment with the findings reported by Casini et al. for other
gold(III) anticancer agents.[5] In other words, our compounds
undergo an “activation” process (i.e. release of one or both
halide ligands from the tetracoordinated gold(III) center), re-
quired to react with the possible cellular targets and, hence, to
trigger the antitumor effects. On the other hand, based on the
redox properties (oxidizing) of the metal ion, a reductive step
for the AuIII center cannot be ruled out a priori when studying
the mechanism of action of this class of potential pharmaceuti-
cals.
Experimental Section
Chemicals
KAuBr4·2H2O and KAuCl4·2H2O were purchased from Alfa Aesar,
[D6]DMSO from Aldrich, ammonium pyrrolidinedithiocarbamate
from Fluka, and P4O10 from AnalaR Normapur–Prolabo. Dulbecco’s
modified Eagle medium (DMEM) was purchased from Euroclone.
All other reagents and solvents (from Aldrich or Fluka) were of
high purity and used without further purification. SAOS-2 osteosar-
coma cells, HeLa cervical adenocarcinoma cells, and HCT116 color-
ectal carcinoma cells were purchased from the American Type Cul-
ture Collection (ATCC). MEF-NF1¢/¢ cells were kindly provided by
Prof. Reuven Stein (George S. Wise Faculty of Life Sciences, Tel Aviv
University, Israel).
Instrumentation and general procedures
Elemental analysis was performed using a Carlo Erba 1108 CHNS-O
microanalyser (CE Instruments Ltd. , Wigan, UK).
FT-IR spectra were recorded at 298 K under N2 atmosphere in Nujol
between two polyethylene tablets on a Nicolet Nexus 870 FT-IR
spectrophotometer (Nicolet Instrument Technologies, now Thermo
Scientific, Waltham, USA) in the range 50–600 cm¢1 (200 scansions,
4 cm¢1 resolution), and in solid KBr on a Nicolet Nexus 5SXC FT-IR
spectrophotometer (32 scansions, 2 cm¢1 resolution) in the range
400–4000 cm¢1. Data processing was carried out using OMNIC ver-
sion 5.1 (Thermo Scientific, Waltham, USA).
All 1D 1H NMR and 2D spectra were acquired in [D6]DMSO at
298 K on a Avance DRX300 spectrophotometer (Bruker, Billerica,
USA) equipped with a broadband inverse (BBI) [1H, X] probehead.
Typical acquisition parameters for 1D 1H NMR spectra (1H:
300.13 MHz): 64–128 transients, spectral width 12 kHz, using 32 k
data points and a delay time of 3.0 s. Spectra were processed by
exponential weighting with a resolution of 0.5 Hz and a line-broad-
ening threshold of 0.1 Hz. Typical acquisition parameters for 2D
[1H,13C] HMBC NMR spectra (1H: 300.13/13C: 75.48 MHz): 512 transi-
ents of 16 scans/block, spectral width 7.5/18.8 kHz, 1 k/1 k data
points and a delay time of 2.0 s. Sequences were optimized for
1J(13C,1H)=145 Hz/nJ(13C,1H)=5 Hz with no 1H decoupling. Spectra
were processed by using sine-square weighting with a resolution
of 1.0/3.0 Hz and a line-broadening threshold of 0.3/1.0 Hz. Data
processing was carried out by means of MestReNova version 6.2
(Mestrelab Research, Escondido, USA). Chemical shifts were refer-
enced to the characteristic signal of the solvent by considering ex-
ternal tetramethylsilane (TMS).
Thermogravimetric (TG) and differential scanning calorimetry (DSC)
curves were recorded on a thermobalance equipped with a DSC
2929 calorimeter (TA Instruments, New Castle, USA). Measurements
were carried out in the range 25–1300 8C in alumina crucibles
under air (flux rate 30 cm3min¢1) at a heating rate of 5 8C min¢1,
using alumina as reference.
Electronic spectra were acquired at 37 8C in the range 250–500 nm
using a Cary 100 UV/Vis double beam spectrophotometer (Agilent,
Santa Clara, USA) (1 cm optical path, quartz cuvettes), using fresh
solutions of the samples in DMSO. With respect to the studies in
0.9% (w/v) NaCl solution, compounds 1 and 2 were dissolved in
DMSO beforehand and subsequently diluted with saline solution
(~1% v/v DMSO) to yield a final concentration of 100 mm. For the
kinetic studies, the initial time (time zero) was set upon the com-
plete dissolution of the complex.
Synthesis of the gold(III) complexes
To an aqueous solution of KAuX4·2H2O (X=Br, Cl ; 0.6 mmol), the
ligand NH4(PDT) (0.6 mmol) was added dropwise while stirring at
rt, giving rise to the immediate precipitation of a solid. After
10 min, the crude product was isolated by centrifugation
(5,000 rpm, 15 min)and washed with H2O and diethyl ether. Both
complexes were then dried in vacuo in the presence of P4O10, with
the final yield in the range of 85–90%.
Dibromido[N-dithiocarboxy-kS,kS’-pyrrolidine]gold-(III)
(AuIIIBr2(PDT), 1) Orange powder (89.6%): soluble in DMSO, ace-
tone, and dimethylformamide (DMF), slightly soluble in CH3CN and
CH2Cl2, insoluble in H2O, EtOH, MeOH, isopropanol, CCl4, and dieth-
yl ether; FT-IR (KBr): v˜max=2971–2849 (n, CH2), 1583 (n, N¢CSS),
1447 (n, CH2), 943 cm
¢1 (na, S¢C¢S); FT-IR (Nujol): v˜max=537 (ns, S¢
C¢S), 411 (na, S¢Au¢S), 371 (ns, S¢Au¢S), 240 (na, Br¢Au¢Br),
218 cm¢1 (ns, Br¢Au¢Br) ; 1H NMR (300.13 MHz, [D6]DMSO, 298 K):
d=2.06 (m, 4H, CH2CH2N); 3.81 ppm (m, 4H, CH2N);
13C NMR
(75.48 MHz, [D6]DMSO, 298 K): d=23.35 (CH2CH2N), 50.87 (CH2N),
188.32 ppm (CSS); Anal. calcd for C5H8AuBr2NS2 (MW=503.81): C
11.94, H 1.60, N 2.78, S 12.75, found: C 12.05, H 1.60, N 2.74, S
12.80; TG (air): calcd weight loss to Au(0) ¢60.91%, found
¢59.95%.
Dichlorido[N-dithiocarboxy-kS,kS’-pyrrolidine]gold-(III)
(AuIIICl2(PDT), 2) Yellow ochre powder (85.3%): soluble in DMSO,
acetone, and DMF, slightly soluble in CH3CN and CH2Cl2, insoluble
in H2O, EtOH, MeOH, isopropanol, CCl4, and diethyl ether; FT-IR
(KBr): v˜max=2980–2866 (n, CH2), 1586 (n, N¢CSS), 1439 (n, CH2),
942 cm¢1 (na, S¢C¢S); FT-IR (Nujol): v˜max=538 (ns, S¢C¢S), 413 (na,
S¢Au¢S), 375 (ns, S¢Au¢S), 362 (na, Cl¢Au¢Cl), 315 cm¢1 (ns, Cl¢
Au¢Cl) ; 1H NMR (300.13 MHz , [D6]DMSO, 298 K): d=2.06 (m, 4H,
CH2CH2N), 3.82 ppm (m, 4H, CH2N);
13C NMR (75.48 MHz,
[D6]DMSO, 298 K): d=23.41 (CH2CH2N), 51.10 (CH2N), 188.58 ppm
(CSS); Anal. calcd for C5H8AuCl2NS2 (MW=412.13): C 14.50, H 1.95,
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N 3.38, S 15.49, found: C 14.56, H 1.92, N 3.34, S 15.48; TG (air):
calcd weight loss to Au(0) ¢52.21%, found ¢51.91%.
Cell viability assay
Cell viability was measured using the Resazurin-based In Vitro Toxi-
cology Assay Kit (Sigma-Aldrich, St. Louis, USA). Cells (40,000/well)
were plated into 96-well microplates the day before the experi-
ment. After the 3 h treatments with compounds 1 or 2, the Resa-
zurin-based reagent was added. Then, cells were maintained at
37 8C for an additional 2 h, and the absorbance at 595 nm was de-
tected using the iMark microplate reader (BioRad, Hercules, USA).
All treatments were carried out in DMEM supplemented with
l-Glutamine (Euroclone), penicillin (100 UmL¢1, Euroclone), and
streptomycin (100 mgmL¢1, Euroclone) distributed into each well
(200 mL) of a 96-well cell culture plate. Stock solutions of all com-
plexes were made in DMSO and then diluted with complete
medium in such a way that the final amount of solvent in each
well did not exceed 0.4% (v/v). Cytotoxicity data were expressed
as IC50 values (Table 5), that is the concentration of the complex in-
ducing a 50% decrease in cell number compared with control cul-
tures.
ROS measurements
ROS measurements were performed using the probe 5-(and-6)-
chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate, acetyl
ester (CM-H2DCFDA, 1 mm, Molecular Probes, Carlsbad, USA). Cells
(10,000/well) were plated the day before the experiment, and CM-
H2DCFDA was added with treatments in DMEM supplemented
with 0.5% fetal bovine serum (FBS) without bicarbonate. Cells
were maintained at 37 8C without CO2 during the experiment, and
the fluorescence (lex=485 nm, lem=538 nm) was recorded using
a Fluoroskan Ascent FL plate reader (Thermo Fisher Scientific, Wal-
tham, USA) at different time points.
Measurement of mitochondrial Ca2+ retention capacity
The CRC assay was used to assess PTP opening by following trains
of Ca2+ pulses which were measured fluorimetrically at 25 8C in the
presence of the Ca2+ indicator Calcium Green-5N (1 mm, lex=
505 nm, lem=535 nm, Molecular Probes). We performed CRC ex-
periments either on isolated mitochondria or on whole cells placed
in an isotonic buffer (130 mm KCl, 1 mm Pi-Tris (Pi : inorganic phos-
phate), 10 mm Tris/3-(N-morpholino)propansulfonic acid (MOPS),
10 mm Tris/ethylene glycol tetraacetic acid (EGTA), 5 mm gluta-
mate/2.5 mm malate, pH 7.4). Whole-cell CRC was carried out after
3 h treatment with compound 1, followed by the plasma mem-
brane permeabilization with the nonionic detergent digitonin,
which is highly selective for cholesterol-enriched membranes and
does not damage the mitochondrial membranes. Cells were
washed with phosphate-buffered saline (PBS, pH 7.4) and then per-
meabilized with 150 mm digitonin (15 min, 4 8C) in a buffer com-
posed of 130 mm KCl, 1 mm Pi-Tris, 10 mm Tris/MOPS, and 1 mm
Tris/EGTA (pH 7.4). Digitonin was then washed away by spinning
cells in the same buffer (15,000 rpm, 30 min) and changing the
EGTA/Tris concentration to 0.1 mm, and the number of cells was
carefully assessed before starting each experiment. Mitochondria
(0.5 mgmL¢1) or permeabilized cells (7Õ106 cells per experiment)
were then placed in the presence of the Ca2+ indicator Calcium-
Green-5N, which does not permeate mitochondria, and were ex-
posed to Ca2+ spikes (10 mm and 5 mm, respectively). Drops in fluo-
rescence were used to assess mitochondrial Ca2+ uptake. PTP
opening was detected as an increase in fluorescence. Pore inhibi-
tors, such as cyclosporine A, are expected to enhance the thresh-
old of Ca2+ concentration required to trigger the permeability tran-
sition, that is, the number of spikes before a sudden and marked
fluorescence increase occurs.
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